Compare FuelCell Energy Inc (FCEL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? FuelCell Energy Inc trades at $19.53 (market cap $1.59B), while Regeneron Pharmaceuticals Inc trades at $807.36 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 52.3× FuelCell Energy Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | REGN | |
|---|---|---|
Market Cap | $1.59B | $83.19B |
Sector | Industrials | Health |
52-Week High | $36.01 | $812.27 |
52-Week Low | $3.92 | $545.94 |
Enterprise Value | $1.43B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $20.43, up 0.54% today, near the analyst consensus target of $20.75. The stock shows a bearish technical signal with negative moving averages, while fundamentals reveal persistent losses: revenue grew to $158.16M in 2025 but net income margin was -132.41%. Recent news highlights partnerships with Siemens and AI data center demand as growth catalysts, though cash flow from operations remains negative at -$125.29M.
FCEL presents high-risk growth potential driven by alternative energy tailwinds and strategic alliances, but investment is speculative due to unprofitability, cash burn, and competitive pressures. Analysts are split evenly between Buy and Hold ratings, reflecting cautious optimism amid financial challenges. The stock's outlook hinges on execution toward profitability and scaling commercial projects.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
